Literature DB >> 7550323

Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene.

S D Colman1, C A Williams, M R Wallace.   

Abstract

Neurofibromatosis type 1 (NF1) is one of the most common human autosomal dominant diseases. NF1 is characterized by café-au-lait spots (CLS), axillary freckles and Lisch nodules of the iris. Another hallmark of NF1 is the development of neurofibromas, benign tumours that arise from peripheral nerve sheaths. NF1 patients also have an increased incidence of certain malignant tumours. Malignancies in NF1 are believed to follow the 'two-hit' hypothesis, in which one allele is constitutionally inactivated while the other allele is subsequently inactivated ('second hit') at the somatic level. This hypothesis has not, however, been fully tested in the aetiology of benign neurofibromas. This is a crucial issue since it addresses not only the basic mechanism behind the genesis of neurofibromas, but may also indicate a mechanism common to many or all NF1 features. Using both NF1 intragenic polymorphisms as well as markers from flanking and more distal regions of chromosome 17, we have investigated loss of heterozygosity (LOH) in 22 neurofibromas from five unrelated NF1 patients. Eight of these tumours revealed somatic deletions involving NF1, indicating that inactivation of NF1 is associated with at least some neurofibromas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7550323     DOI: 10.1038/ng0995-90

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  47 in total

1.  Hereditary spinal neurofibromatosis: a rare form of NF1?

Authors:  M Poyhonen; E L Leisti; S Kytölä; J Leisti
Journal:  J Med Genet       Date:  1997-03       Impact factor: 6.318

2.  NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors.

Authors:  A Perry; K A Roth; R Banerjee; C E Fuller; D H Gutmann
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.

Authors:  Trent R Hummel; Walter J Jessen; Shyra J Miller; Lan Kluwe; Victor F Mautner; Margaret R Wallace; Conxi Lázaro; Grier P Page; Paul F Worley; Bruce J Aronow; Elizabeth K Schorry; Nancy Ratner
Journal:  Clin Cancer Res       Date:  2010-08-25       Impact factor: 12.531

4.  Confirmation of a double-hit model for the NF1 gene in benign neurofibromas.

Authors:  E Serra; S Puig; D Otero; A Gaona; H Kruyer; E Ars; X Estivill; C Lázaro
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

5.  A search for evidence of somatic mutations in the NF1 gene.

Authors:  A M John; M Ruggieri; R Ferner; M Upadhyaya
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

6.  Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation.

Authors:  G P Nielsen; A O Stemmer-Rachamimov; Y Ino; M B Moller; A E Rosenberg; D N Louis
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

7.  A multiplex-PCR test for EVI2A and EVI2B polymorphisms within the human NF1 gene.

Authors:  S A Rasmussen; V T Ho; S D Colman; C R Abernathy; M R Wallace
Journal:  Mamm Genome       Date:  1996-03       Impact factor: 2.957

8.  "Mistakes happen": somatic mutation and disease.

Authors:  F Qian; G G Germino
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

9.  Somatic mosaicism in a patient with neurofibromatosis type 1.

Authors:  S D Colman; S A Rasmussen; V T Ho; C R Abernathy; M R Wallace
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

10.  NF1 loss disrupts Schwann cell-axonal interactions: a novel role for semaphorin 4F.

Authors:  Simona Parrinello; Luke A Noon; Marie C Harrisingh; Patrick Wingfield Digby; Laura H Rosenberg; Catherine A Cremona; Pedro Echave; Adrienne M Flanagan; Luis F Parada; Alison C Lloyd
Journal:  Genes Dev       Date:  2008-12-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.